199 results on '"Arban, Roberto"'
Search Results
2. Dopamine modulating agents alter individual subdomains of motivation-related behavior assessed by touchscreen procedures
3. Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders
4. Discovery of BI-9508, a Brain-Penetrant GPR88-Receptor-Agonist Tool Compound for In Vivo Mouse Studies.
5. Whole-brain signatures of functional connectivity after bidirectional modulation of the dopaminergic system in mice
6. Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders
7. Rapid-acting antidepressant drugs modulate affective bias in rats
8. Discovery of BI-9508, a Brain-Penetrant GPR88-Receptor-Agonist Tool Compound for In VivoMouse Studies
9. Investigating neuropsychological and reward-related deficits in a chronic corticosterone-induced model of depression
10. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells
11. Different susceptibility to social defeat stress of BalbC and C57BL6/J mice
12. Strain-specific outcomes of repeated social defeat and chronic fluoxetine treatment in the mouse
13. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats
14. Alterations of behavioral and endocrinological reactivity induced by 3 brief social defeats in rats: Relevance to human psychopathology
15. Transient forebrain over-expression of CRF induces plasma corticosterone and mild behavioural changes in adult conditional CRF transgenic mice
16. Social defeat-induced contextual conditioning differentially imprints behavioral and adrenal reactivity: A time-course study in the rat
17. Effects of pro‐depressant and immunomodulatory drugs on biases in decision‐making in the rat judgement bias task
18. Conditioning properties of social subordination in rats: Behavioral and biochemical correlates of anxiety
19. Effects of pro‐depressant and immunomodulatory drugs on biases in decision‐making in the rat judgement bias task.
20. Anxiolytic-like effect of the selective Neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze
21. Characterisation of the selective 5-HT 1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity
22. Single exposure to social defeat increases corticotropin-releasing factor and glucocorticoid receptor mRNA expression in rat hippocampus
23. T178. MICROPIPETTE-GUIDED DRUG ADMINISTRATION (MDA) METHOD AS A NOVEL PHARMACOLOGICAL TREATMENT METHOD IN MICE: PRECLINICAL VALIDATION USING RISPERIDONE IN THE MATERNAL IMMUNE ACTIVATION MODEL OF NEURODEVELOPMENTAL DISORDERS
24. S31. ENHANCEMENT OF SYNAPTIC PLASTICITY BY COMBINATION OF PDE2 AND PDE9 INHIBITION PRESUMABLY VIA PRE- AND POST-SYNAPTIC MECHANISMS
25. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania
26. V1b Receptors: New Probes for Therapy
27. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): In vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity
28. Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist
29. Expression analysis of brain-derived neurotrophic factor (BDNF) mRNA isoforms after chronic and acute antidepressant treatment
30. S188. The Phosphodiesterase-9 Inhibitor BI 409306 Attenuates Social Interaction and Dopaminergic Deficits in Adult Offspring of poly(I:C)-Based Maternal Immune Activation Neurodevelopmental Mouse Model
31. F21. THE PHOSPHODIESTERASE-9 INHIBITOR BI 409306 ATTENUATES SOCIAL INTERACTION AND DOPAMINERGIC DEFICITS IN ADULT OFFSPRING OF POLY(I:C)-BASED MATERNAL IMMUNE ACTIVATION NEURODEVELOPMENTAL MOUSE MODEL
32. The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging
33. Regional Cerebral Blood Volume Mapping after Ischemic Lesions
34. F196. Transgenic Overexpression of the Type III Isoform of Neuregulin 1 in Mice Induces Abnormalities on Auditory Event Related EEG Biomarkers Related to Schizophrenia Accompanied by Reduction of Parvalbumin Positive Interneurons in the Prefrontal Cortex
35. S141. TRANSGENIC OVEREXPRESSION OF THE TYPE III ISOFORM OF NEUREGULIN 1 IN MICE INDUCES ABNORMALITIES ON AUDITORY EVENT RELATED EEG BIOMARKERS RELATED TO SCHIZOPHRENIA
36. Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator
37. 669. GPR52 Agonists Represent a Novel Approach to Treat Cognitive Deficits Associated with Schizophrenia
38. Design and Synthesis of Novel Tricyclic Benzoxazines as Potent 5-HT1A/B/DReceptor Antagonists Leading to the Discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045)
39. P4‐010: Improving Cognitive Function in Rodents Via Increasing Glycine Levels in Brain by the Novel Glycine Transporter‐1 Inhibitor BI 425809
40. The characterization of a novel V1b antagonist lead series
41. Pyrrolo[1,2- a]pyrazine and pyrazolo[1,5- a]pyrazine: Novel, potent, and selective series of Vasopressin 1b receptor antagonists
42. 5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1 H)-quinolinones and 3,4-dihydro-2(1 H)-quinolinones: Dual-acting 5-HT 1 receptor antagonists and serotonin reuptake inhibitors. Part 3
43. GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species
44. Poster #M15 PRE-SYNAPTIC LOCALIZATION OF PDE2 ENZYME AND PHARMACOLOGICAL CHARACTERIZATION OF THE PDE2 INHIBITOR PF-999 IN MODELS RELATED TO COGNITIVE SYMPTOMS OF SCHIZOPHRENIA
45. Antimanic Efficacy of a Novel Kv3 Potassium Channel Modulator
46. IMPROVING COGNITIVE FUNCTION IN RODENTS VIA INCREASING GLYCINE LEVELS IN BRAIN BY THE NOVEL GLYCINE TRANSPORTER-1 INHIBITOR BI 425809
47. Differential behavioral, physiological, and hormonal sensitivity to LPS challenge in rats
48. 5-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2(1H)-quinolinones and 3,4-dihydro-2(1H)-quinolinones: Dual-acting 5-HT1 receptor antagonists and serotonin reuptake inhibitors. Part 3
49. Pyrrolo[1,2-a]pyrazine and pyrazolo[1,5-a]pyrazine: Novel, potent, and selective series of Vasopressin1b receptor antagonists
50. Design and Synthesis of Novel Tricyclic Benzoxazines as Potent 5-HT1A/B/D Receptor Antagonists Leading to the Discovery of 6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4H-imidazo[5,1-c][1,4]benzoxazine-3-carboxamide (GSK588045)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.